A recent small study of 4 patients evaluated the first-in-class CAIX-binding radiolabeled peptide, DPI-4452, conjugated to Gallium-68 (68Ga), as an effective diagnostic imaging method to identify ccRCC lesions.80 Administration of 68Ga-DPI-4452 demonstrated intense and sustained radiotracer uptake in RCC tumors with low background activity in normal kidney, liver, and bone marrow tissues, making it a promising diagnostic application for patient selection in future studies on CAIX-directed radioligand therapies. This evidence concerns the gene CA9 and nonpapillary renal cell carcinoma.